Adding camrelizumab and rivoceranib to transarterial chemoembolization (TACE) significantly prolonged progression-free ...

BRAF V600E-mutant metastatic colorectal cancer (CRC) was associated with poor clinical outcomes in patients receiving ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Naporafenib is Erasca’s main candidate, and it has Fast Track status for NRASm melanoma. See why I rate ERAS stock as a buy.

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

From iconic revivals to ambitious debuts, 2025 is poised to redefine PC gaming with stunning visuals and bold new titles.